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On September 6 and 7, 2009 a meeting was held in London to identify and discuss what are perceived to
be current roadblocks to effective hepatocyte transplantation as it is currently practiced in the clinics and,
where possible, to offer suggestions to overcome the blocks and improve the outcomes for this cellular
therapy. Present were representatives of most of the active clinical hepatocyte transplant programs along
with other scientists who have contributed substantial basic research to this field. Over the 2-day sessions
based on the experience of the participants, numerous roadblocks or challenges were identified, including
the source of cells for the transplants and problems with tracking cells following transplantation. Much of
the discussion was focused on methods to improve engraftment and proliferation of donor cells posttrans-
plantation. The group concluded that, for now, parenchymal hepatocytes isolated from donor livers remain
the best cell source for transplantation. It was reported that investigations with other cell sources, including
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stem cells, were at the preclinical and early clinical stages. Numerous methods to modulate the immune
reaction and vascular changes that accompany hepatocyte transplantation were proposed. It was agreed that,
to obtain sufficient levels of repopulation of liver with donor cells in patients with metabolic liver disease,
some form of liver preconditioning would likely be required to enhance the engraftment and/or proliferation
of donor cells. It was reported that clinical protocols for preconditioning by hepatic irradiation, portal vein
embolization, and surgical resection had been developed and that clinical studies using these protocols would
be initiated in the near future. Participants concluded that sharing information between the groups, including
standard information concerning the quality and function of the transplanted cells prior to transplantation,
clinical information on outcomes, and standard preconditioning protocols, would help move the field forward
and was encouraged.
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INTRODUCTION good quality cells. Hepatocyte transplantation must
compete for organs with liver transplantation, the well-
established treatment for liver disease. Hence, the cur-Liver transplantation is currently the treatment of
choice for patients with end-stage liver disease and acute rent source of hepatocytes is mainly donor organs deemed
unsuitable for whole organ transplantation, which areliver failure (ALF). However, the number of patients
waiting for a liver transplant greatly outnumbers avail- often of marginal quality. Organs from brain-dead donors,
organs from donation after cardiac death (DCD) withable donors. Even with improvements in donor schemes,
the use of broader donor criteria, and recent advances in less than 40 min of warm ischemia, or organs from
extended age donors are typical sources for cell isola-surgical techniques, such as split-liver and living-related
liver donor grafts, there has only been a small increase tion. If the efficacy of hepatocyte transplantation were
firmly established, other sources of tissue such as a splitthe number of transplants (61).
Hepatocyte transplantation (HT) has been performed of a liver being used for OLT or even a live donor seg-
ment could be considered when the benefit of the cellu-as an alternative to orthotopic liver transplantation
(OLT) to treat some liver-based inborn errors of metabo- lar transplant were judged to be equal to or greater than
risk of the added surgical procedure.lism and liver failure (18,49,55). Clinical observations
have demonstrated the safety of the procedure and
patients who have undergone HT showed clinical Cell Quality and Clinical Outcome
improvement and/or partial correction of the underlying The outcome of HT is closely related to the quality
metabolic defect. However, in the majority of the cases, of the hepatocytes transplanted. If fresh cells are trans-
sustained benefits were not observed. planted, rapid and sensitive assays to evaluate their via-
In an effort to identify and discuss possible strategies bility and function are needed in order to determine their
to overcome the limitations of the technique, experts in suitability for transplantation.
the field of human hepatocyte transplantation met in In the majority of the published reports of hepatocyte
London on September 6 and 7, 2009. The meeting focused transplantation trypan blue exclusion was the sole test
on alternative sources of hepatocytes needed to over- for cell viability. Trypan blue exclusion reflects cell via-
come the shortage of organ donors and the lack of stan- bility at that point in time based on cell membrane integ-
dardization of the quality of cells used, which make it rity, but its correlation with cell metabolic function and
difficult to compare the results of human hepatocyte the potential of cells to engraft has yet to be determined.
transplantation reported in the literature. Clinical appli- Given its simplicity, the trypan blue exclusion test
cation of techniques to precondition the liver with the should be performed on cells at the end of isolation,
aim of improving hepatocyte engraftment and repopula- after thawing cryopreserved cells, and pre- and postinfu-
tion after transplantation was identified as a key issue. sion. ATP production is also a quality assay that may
Overall, the purpose of this meeting was to consider new prove efficient to estimate cell viability and functional
techniques that could be applied to improve the outcome activity; however, until proven otherwise, we assume
of clinical HT. This review summarizes the content of that engraftment in the liver will correlate with the plat-
the meeting and as a result reflects the topics discussed ing efficiency of cells—that is, the ability of cells to
and comments made by the attendees. It is thus not a attach and survive long term (3–7 days) on culture
comprehensive review of the literature or an exhaustive plates precoated with a suitable substrate.
review of each topic. Other assays to determine the quality of the cells that
could be performed within 2 h of cell isolation were
HUMAN HEPATOCYTE TRANSPLANTATION discussed in the meeting. Donato et al. (13) recently dem-
onstrated that it is possible to determine up to 10 parame-The major challenge that this field is facing is the
limited supply of donor organs that are available to isolate ters to estimate the quality of hepatocyte preparations
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in 1 h. In addition to the trypan blue exclusion test and respiratory chain enzyme activity, increased mitochon-
drial permeability, and impaired respiration (56,59).plating efficiency, assays were used to determine the cell
metabolic competence, urea synthesis and drug-metabo- Targeted analysis of specific liver functions may be
particularly useful for transplants of patients with meta-lizing P450 activities (CYP1A2, 2A6, 2C9, 2C19, 2D6,
2E1, and 3A4) performed by mass spectrometry in hepa- bolic disorders because cells could be screened for use-
ful levels of the expression of the metabolic activitytocyte suspensions. Determination of the metabolic sig-
nature of the cells using techniques such as 1H nuclear missing in the recipient prior to transplantation. To date,
liver-based inborn errors of metabolism have been themagnetic resonance (NMR) spectroscopy, and noninva-
sive quantification of cellular mitochondrial respiration main indication for hepatocyte transplantation, in partic-
ular urea cycle defects and Crigler-Najjar syndrome typecan also be performed rapidly and can provide valuable
information on the quality of cells. However, they need 1. Recently, Bonora-Centelles et al. (7) proposed spe-
cific assessment of cells prior to infusion for urea syn-sophisticated equipment that may not be available in
each cell isolation laboratory. They are more relevant thesis from ammonia and UDP-glucuronosyltransferase
1A1 activity, with an assay using β-estradiol as sub-when hepatocytes are cryopreserved and there is more
time to perform the assays. strate, allowing the possibility of customizing cell prepa-
ration for patients affected with disorders in theseHowever, studies where the endpoint of the meta-
bolic process results in a fluorescent, luminescent, or pathways. As indicated above, because of time con-
straints with freshly isolated cells, assays of specificvisible colored metabolite can provide rapid and sensi-
tive methods to assess a wide variety of hepatic func- function prior to transplantation have only been con-
ducted on previously cryopreserved cells.tions within 2 h of cell isolation with fewer than 40,000
cells with simple equipment readily available in most
STANDARD INFORMATION TO BE REPORTEDlaboratories (luminometers and fluorescent spectropho-
FROM CELLULAR TRANSPLANTStometers) (21). It is not currently known which tests
will be useful to predict long-term engraftment and The participants of the meeting concurred that in
order to make progress in the field it would be helpfulfunction following transplantation, but the collection of
data on a standard battery of assays designed to mea- to be able to directly compare clinical outcomes after
hepatocyte transplantation when performed by differentsure multiple hepatic functions combined with retro-
spective analysis of cellular function, in vivo, should groups. Therefore, it would be necessary to report all
the collected data on the quality of the cells to facilitateprove useful and is encouraged.
Engraftment efficiency in suitable recipient animals comparison of patients’ outcomes (retrospective data).
Details of the donor selection criteria, such as age, sex,is considered the best surrogate marker of cells useful
for transplant. Because of the time frame for the study, previous drug treatments, warm and/or cold ischemia
time, presence of steatosis, and reason for rejecting liverthis test can only be interpreted in retrospect. Even an
assessment of the engraftment in animals has limita- tissue for organ transplantation, are some of the data that
would be relevant when analyzing the outcomes aftertions, as the efficacy of human hepatocyte engraftment
and repopulation of a rodent liver may be suboptimal hepatocyte transplantation. If cells from multiple donors
have been transplanted, individualized reports of thedue to incompatibilities of growth factor and cytokine
response and cell-to-cell and cell-to-matrix interactions. data would give more valuable information. In the case
of split-livers, information about the outcome in the liverSome centers in Europe only transplant cryopre-
served hepatocytes that have been characterized for a tissue recipient(s) should be obtained, as it could indi-
rectly assess the quality of cells used for hepatocytenumber of functions prior to clinical transplantation.
Cryopreservation allows cell banking and flexibility in transplantation. Systematic biopsy of the liver before
processing could be helpful not only for histologicalthe timing of cell delivery to patients. Discrepancies in
the clinical results between different centers and even analysis, but also for molecular analysis of parameters
such as oxidative stress and apoptosis. At present, it isdifferent patients in the same center may, in part, be
related to differences in cell quality after isolation and not known which parameters of cell quality correlate
best with engraftment or a favorable clinical outcome. Itcryopreservation, so the use of banked hepatocytes
offers the advantage or more time for extensive micro- was concluded that if standard information concerning
the quality assessment of the cells prior to transplanta-biological testing and quality control studies prior to
transplantation. However, freshly isolated cells generally tion and the clinical outcome was compiled in a data-
base, such an analysis would become feasible.have better viability and plating efficiency than cryopre-
served cells, and are likely to engraft better than pre-
WHAT ARE THE ALTERNATIVES?viously cyropreserved cells. Studies have shown that
cryopreservation is associated with mitochondrial dam- To move the field forward, a reliable source of cells
is needed, but at present it is not clear which cellages, loss of capacity for ATP synthesis and abnormal
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source(s) is/are the most promising. The characteristics example, around 30 fetal livers (12 weeks gestation)
would be needed. A recent report of a child with ataxiaof the cell source might vary from cells expressing the
specific missing protein or enzyme to cells presenting telangiectasia treated with intracerebellar and intrathecal
injection of human fetal neural stem cells, who devel-full hepatocyte function (hepatocyte-like cells) accord-
ing to the indication for liver cell transplantation. Cells oped a multifocal brain tumor 4 years after the experi-
mental treatment, raises concerns over the safety of thisbeing considered for potential clinical application include
fetal human hepatocytes, mesenchymal stem cells (MSCs) experimental therapeutic approach. Molecular and cyto-
genetic studies showed that the tumor was of non-hostfrom a variety of sources including liver, amnion epithe-
lial cells, and xenotransplants with porcine hepatocytes. origin, suggesting it was derived from the transplanted
neural stem cells (2). This underlines the importance ofIt was appreciated that for some cell sources, it would
take some time before clinical application was feasible. the process of informed consent as a central component
of any experimental study giving enough information to
Fetal Liver Progenitor Cells patients to make sure they understand and accept the
potential risks.Hepatoblasts, the hepatic progenitor cell population
present in fetal and neonatal livers, rapidly decline in
Mesenchymal Cells and Hepatocyte Progenitorsnumber with age, and are almost undetectable in adult
Derived From Liverlivers (52). Numerous animal experiments have been
performed to evaluate the capacity of human fetal liver Bone marrow-derived MSCs are already widely used
in medicine and currently there are over 60 MSC ongo-cells to engraft and repopulate the recipient liver. Trans-
plantation of cryopreserved hepatoblasts from early fetal ing clinical trials with no safety risk demonstrated in
humans so far (45). MSCs, which are usually autolo-livers (11–13 weeks of gestation) into the liver of new-
born athymic mice resulted in up to 10% of liver repop- gous, can be isolated, expanded, and utilized for a vari-
ety of therapeutic applications, including the treatmentulation and cells expressed markers of differentiated
adult hepatocytes (39). These results could not be repro- of inflammatory, cardiovascular, and orthopedic diseases.
Mesenchymal-like cells have also been isolated fromduced in an immunodeficient heterozygous albumin-
urokinase-type plasminogen activator (uPA) mouse, adult liver tissue. This cell population can proliferate to
a certain extent and differentiate into hepatocyte-likewhere transplanted human fetal liver cells (14–17 weeks
of gestation) resulted in a lower degree of liver repopu- cells with more specific hepatocytic phenotype com-
pared to bone marrow- or Wharton’s jelly-derived cellslation than adult human hepatocytes (25). However, dif-
ferences in age (newborn or adult) in host or donor cells (8). Studies conducted in vitro have shown a range of
hepatic functions including drug metabolizing enzymesand/or species differences may also affect repopulation
and maturation. Recently it was demonstrated by (30). Preliminary studies in immunodeficient uPA mice
confirmed their ability to engraft and differentiate into111indium labeling of cells that the biodistribution of fetal
liver cells and adult hepatocytes were similar and hepatocyte-like cells in vivo (44). Recent reports suggest
that they also play a role of trophic support in injuredrestricted to the liver, without translocation into pulmo-
nary or systemic circulations (10). Quantification of livers by inhibiting endogenous hepatocyte death and
stimulating their proliferation (62,64). In culture, theymature gene expression levels in donor cells was not
investigated in any of these studies, so the level of matu- enter a phase of replicative senescence after a limited
number of population doubling (5).ration of the fetal cells posttransplant remains unknown.
Since mature liver genes are frequently expressed at Small cells, termed liver-derived progenitor cells
(LDPC), have been cultured, in vitro, from cells derived1–5% of normal levels found in adults, it is important
to determine the rate at which fetal hepatoblasts mature by collagenase perfusion of rodent liver. These cells pro-
liferate extensively in culture and can give rise to hepa-following transplant before their suitability for liver sup-
port can be assessed. tocytes after engraftment into the liver (9).
The use of manipulated cells is considered a medici-There are a number of potential advantages in using
fetal cells. Cell viability is normally high after cell isola- nal product, and most preclinical studies are focused on
safety. Although there have been no safety problems sotion, they maintain some stem cell properties, can be
expanded in culture, and, in rodents, without species far, studies to investigate tumorigenicity, the purity of
the preparations, and cytogenetic studies to assess clonalincompatibilities, these cells have shown significant
liver repopulation capacity. However, at present the clin- chromosomal rearrangements are still needed before
their clinical application. Preclinical safety studies inical application of this cell source is restricted due to the
difficulty in obtaining large numbers of fetal liver cells. nonhuman primates remain highly debated, as these
have not been shown to be more relevant than the stan-To transplant a quantity of cells corresponding to an
estimated 2% of the liver mass of a newborn, for dard toxicology studies in rodents.
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Xenotransplantation hepatocytes encapsulated in alginate administered intra-
peritoneally significantly improved survival in a mouse
model of fulminant hepatic failure (41) and could beXenotransplantation is one possible alternative to
overcome the shortage of donor organs, and pigs repre- worthy of further development.
sent a possible source of liver to obtain liver cells. Pig
hepatocytes represent a readily available source of cells HOW TO IMPROVE LIVER ENGRAFTMENT
for scheduled or emergency transplantation, allowing AND REPOPULATION?
repeated cell infusions if required. The quality of hepa-
The outcome of hepatocyte transplantation has also
tocytes isolated from donor pigs is consistent and, in
been limited by the low efficiency of integration of
contrast to donor human hepatocytes, are not compro-
transplanted cells into the host liver parenchyma. In ani-
mised by comorbidities, warm and/or cold ischemia
mal models, after intraportal transplantation, adult hepa-
injury, and senescence. Furthermore, the risks of infec-
tocytes are restricted to the liver, without translocation
tious disease transmission associated with xenografting
to pulmonary or systemic circulations (10). Similar
of hepatocytes are minimal, if cells are isolated from
results were observed when the biodistribution of human
designated pathogen-free donor pigs.
hepatocytes was analyzed in a clinical setting (6). Most
Preformed antibodies against a particular porcine car-
of the transplanted hepatocytes (>70%) remain wedged
bohydrate moiety (Gal) are responsible for triggering
in the portal spaces and sinusoids, and are recognized as
hyperacute rejection of pig organs transplanted into pri-
“non-self” by the immune system, including Kupffer
mates (20). Gal gene knockout pigs (48) have been
cells and neutrophils, and are cleared within 24–48 h
developed, and the use of their organs for transplantation
(23,29). The presence of cells in the vascular beds is
into nonhuman primates has resulted in prolonged sur-
inevitably associated with inflammation, tissue injury,
vival (36). Lessons learned from islet xenotranplantation
and ischemic events, stimulating the release of vascular
suggest that, unlike vascularized solid organ xenografts,
endothelial growth factor (VEGF) by donor cells and
the rejection of porcine islet xenografts in nonhuman
surrounding hepatocytes and endothelial cells as well as
primates is associated with a predominant T-cell infil-
cytokines by Kupffer cells, which induce vascular per-
trate (19). The demonstration by several groups of pig
meability and sinusoidal endothelium disruption, allow-
islet xenograft survival for months and the recent
ing surviving hepatocytes to reach the space of Disse.
achievement of prolonged insulin independence in dia-
Integration of transplanted hepatocytes into the host
betic monkeys indicates that these cellular xenografts
liver parenchyma requires reconstitution of plasma
do not undergo hyperacute rejection as observed in
membrane structures, which takes around 3–7 days to
vascularized organ transplants (26). Furthermore, no
occur in animal models (23,33). Once engrafted in the
increase in anti-Gal antibody levels were observed, and
liver plates, the transplanted cells can survive indefi-
wild-type pig islets were not more susceptible to early
nitely in syngeneic models. In humans, however, where
posttransplant graft loss than islets from Gal-knockout
allogeneic cells are normally transplanted, after success-
pigs (27,51).
ful engraftment hepatocytes may also face a cell-medi-
Encouraging results were also achieved with trans-
ated immune response, evoked by both CD4+ and CD8+
plantation of porcine hepatocytes into the spleen of
T cells, which may contribute to the gradual loss of graft
cynomolgus monkeys, which were shown to secrete
function that is frequently observed (1,24).
albumin for over 80 days after transplantation under
conventional immunosuppression (43). In addition,
Alternative Site for Transplantationintrasplenic transplantation of porcine hepatocytes into
rats with decompensated liver failure resulted in restora- To date, the liver has been the primary site for hepa-
tocyte transplantation by infusing the cells through thetion of liver function and prolonged survival for a period
of weeks without immunosuppression (42). Regarding portal circulation. Transplantation of cells into extrahe-
patic sites such as the peritoneal infusion of cells hasclinical translation, the immune system of patients with
liver failure is so compromised at the time of transplan- been reported in few clinical cases. Other sites (e.g.,
subrenal, subcutaneous, or intramuscular spaces) aretation that, at least initially, the need for immunosup-
pression would probably be low. The consensus of the being explored (46,47,58,60). The therapeutic potential
of ectopic hepatocyte transplantation has been demon-meeting was to produce more preclinical data in the pig-
to-primate model as a necessary step to further consider- strated in animal models, including hemophilia and
ascorbic acid deficiency (46,60). Much additional workation of pig-to-human HT.
Although not discussed at the meeting, another will be needed before it can be determined if ectopic
transplantation procedures will be practical and viableapproach using xenotransplantation is to microencapsu-
late hepatocytes as a barrier to immune attack. Porcine in the clinic.
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Prevention of Early Loss of Transplanted Cells hepatocytes have the capacity to proliferate, they do
not express this property unless they are induced to pro-Controlling Liver Inflammation. Various approaches
liferate in response to a mitotic stimulus (16). A selec-have been used to improve cell engraftment in preclini-
tive growth advantage of transplanted hepatocytes withcal models. In rodents depletion of neutrophils or Kupffer
near total liver repopulation has been demonstrated incells have improved engraftment of transplanted cells (29,
various animal models where the liver was precondi-35). Recently it was also demonstrated that within 6 h
tioned using drugs that impaired native liver regenera-of syngeneic HT there is upregulation of numerous cyto-
tion, followed by a proliferation stimulus (28,37).kine–chemokine genes associated with activated neutro-
Recent reports indicate that human hepatocytes alsophils and macrophages, including chemokine ligands
have an extensive capacity to proliferate and repopulateand receptors and regulatory cytokines such as tumor
the liver of immunodeficient Fah or urokinase-type plas-necrosis factor-α and interleukin-6 (35). This suggests
minogen activator transgenic mice (4,58). In these stud-targets that could be directly modulated with drugs to
ies, transplantation of primary human cells into the liverimprove cell engraftment. It has also been shown in
resulted in repopulation of the mouse liver with humanrodents that during the early clearance of transplanted
hepatocytes that maintained human hepatocyte-specificcells from the liver the hepatic cyclooxygenase path-
functions including albumin and coagulation factor pro-ways (COX-1 and COX-2) involved in the synthesis of
duction and CYP450 gene expression and metabolicprostaglandins, prostacyclins, thromboxanes, and other
function. Subsequent isolation of human hepatocytesprostanoids are activated. Drugs that specifically block
from the “humanized” mouse liver followed by serialprostaglandin–endoperoxide synthases stimulated stel-
transplantation through four generations of mice waslate cells to release hepatocyte protective factors, such
demonstrated, which required an estimated greater thanas hepatocyte growth factor (HGF) and VEGF, and
1010-fold expansion of the population of cells originallymatrix-type metalloproteinases, which regulate hepatic
transplanted. Thus, in this animal model, human hepato-remodeling and improved cell engraftment (15).
cytes even from individuals >60 years of age still dis-
play remarkable proliferation potential. Thus, in theInhibiting Activation of Coagulation. Isolated hepa-
clinical transplants, the lack of robust proliferation in thetocytes were shown to express both soluble and mem-
recipient liver following transplantation is most likelybrane-bound forms of tissue factor, which have
due to lack of regenerative stimulus on the part of theprocoagulant activity, contributing to early loss of trans-
host. Methods to increase proliferation of transplantedplanted cells. In vitro experiments demonstrated that N-
cells should have a high probability of success.acetyl-L-cysteine inhibits this tissue factor-dependent
activation of coagulation (57).
Hepatic Irradiation. In animal models, hepatic irra-
Controlling Vascular Changes in the Liver. Splanch- diation at low dose has been shown to improve cell
nic vasodilators, such as nitroglycerine, have been shown engraftment and proliferation. Enhanced engraftment is
in rodent models to increase transplanted cell entry into likely mediated by short-term disruption of hepatic
liver sinusoids, which led to improved cell engraftment sinusoidal endothelial cells, observed after 24 h by elec-
and decreased microcirculatory perturbations, without tron microscopy, and by suppression of the phagocytic
significantly increasing intrapulmonary cell transloca- activity of Kupffer cells. Hyaluronic acid, which is
tion (54). cleared from the circulation by sinusoidal endothelial
cells by receptor-mediated endocytosis, was found toReversible Sinusoidal Endothelium Disruption. There
start increasing as early as 6 h after hepatic irradiationis endothelial damage when cells are injected into the
and returned to preirradiation levels in 7 days (63).liver circulation, which is part of the engraftment pro-
Therefore, optimal timing for HT after hepatic irradia-cess and takes around 48 h to resolve. Rats treated with
tion ranges from 1 to 7 days. In addition, hepatic irradia-agents that disrupt hepatic sinusoidal endothelial cells,
tion doses ranging from 15 to 50 Gy in rodents resultedsuch as cyclophosphamide and doxorubicin, accelerated
in a temporary block of the native cell cycle (arrest inthe entry and increased engraftment of transplanted
the G1/S phase), which promoted preferential prolifera-hepatocytes into the liver parenchyma (31,40).
tion of transplanted hepatocytes in response to a mitotic
Liver Preconditioning and Proliferation Stimulus stimulus, resulting in extensive repopulation of the host
liver (32,34,63). However, there is the concern that hepaticThe different strategies used in preclinical models
mentioned above have been shown to improve cell irradiation activates stellate cells, which in the long term
could produce irradiation-induced liver fibrosis (53).engraftment after hepatocyte transplantation; however,
they do not induce subsequent cell proliferation and It is important to take into consideration that there
are species differences in response to hepatic irradiation,liver repopulation. Although it is believed that engrafted
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and rodents are generally more resistant. In cynomolgus in repopulation of 10% of the nonembolized lobe. There
was no regeneration in the embolized lobe. The left lat-monkeys, a single 10 Gy dose of hepatic irradiation was
sufficient to enhance the engraftment of porcine hepato- eral segment used for hepatocyte isolation corresponded
to 20% of the liver mass. However, regeneration studiescytes after transplantation (63). However, with whole
liver irradiation (>40 Gy) the animals developed irradia- did not show significant difference when compared with
liver embolization without resection.tion-induced liver disease and died within 6 weeks.
The human liver is very radiosensitive. A single 30 The use of reversible PVE represents a less invasive
approach to induce liver regeneration. Lainas et al. (38)Gy dose of whole liver irradiation can cause liver failure
due to endothelial damage and consequent veno-occlu- showed that PVE performed in the same nonhuman
primate preclinical model using an absorbable materialsive disease. On the other hand, a third of the liver can
be irradiated with doses as high as 90–100 Gy with no (gelfoam) powder that allows very distal infusion
resulted in a more complete portal obstruction. The pro-adverse consequences to the whole organ, indicating that
the volume of liver irradiated is important in the process. cedure induced significant hepatocyte proliferation and
hypertrophy of the nonembolized lobes. Complete portalAs hepatic irradiation has not yet been used as a liver
preconditioning method for clinical hepatocyte trans- vein recanalization after reversible embolization occurred
on average within 13 days. The material used for embo-plantation, definition of patients and diseases that could
possibly benefit from this technique is important and lization causes some inflammatory reaction, which is
reversible. Longer term follow-up showed that up to 6%was discussed in the meeting. Available data on liver
irradiation for infants <2 years of age is inconclusive, of recipient liver resulted from donor hepatocytes 3
months after transplantation. Comorbidities, such asbut they are at greater risk of developing complications,
such as central nervous system neoplasms and rib cage liver cirrhosis and diabetes, could decrease the extent of
liver regeneration.deformities. For children >2 years, single fractions of
3–5 Gy are definitely safe if performed in focal parts Clinical translation of the technique is underway and
it will be performed as a single procedure, with revers-of the liver, but whether this would promote sufficient
repopulation with donor cells is unknown. ible percutaneous embolization performed first, fol-
lowed by hepatocyte infusion. A slight and transitoryThe safety of the patient is the main concern for the
procedure. Accordingly, it is now considered that increase in the portal pressure normally occurs after
embolization, and should have returned to normal levelshepatic irradiation should be delivered in a single frac-
tion and confined to a portion of one lobe of liver. Care- before cell transplantation is performed.
ful selection of patients is equally important. Cirrhotic
patients should be avoided as their livers are more sensi- Partial Hepatic Resection. Improved techniques and
increased activities at experienced centers have madetive to radiation. The first choice of patients will be
those presenting with diseases in which the therapeutic liver resection and living donor liver transplantation a
common procedure. Hepatectomy as a pretreatment foreffects of transplanted cells can be readily measured and
who are also candidates for organ transplantation, hepatocyte transplantation to induce regeneration and
proliferation should be considered. The surgical proce-should rescue therapy be required if the procedure is not
successful. Donor hepatocytes should be transplanted dure would likely be much safer than when partial
hepatic resections are performed for tumor removal orwithin 7 days of hepatic irradiation, although ideally
after 24 h. If the planned initial studies with these tech- for living donor harvest. The location of the tumor(s)
dictates how the resection will be performed. Forniques establish that liver preconditioning with hepatic
irradiation is safe and results in an improvement in removal of a living donor liver graft, the surgeons need
to consider preservation of vessels in the graft as wellengraftment, this will certainly open new opportunities
in the field of hepatocyte transplantation. as minimizing the ischemic injury to the graft during
surgery. In a recent report from one center, no life-
threatening complications occurred following 100 donorPortal Vein Embolization. Permanent portal vein
embolization (PVE) is a safe procedure that is widely hepatectomies (17). In the case of hepatectomy as a pre-
treatment for hepatocyte transplantation the only con-used in the surgical setting to induce hypertrophy of the
contralateral lobe and prevent postresection liver failure cern for the surgeon will be safety of the patient. The
surgeon will choose the tissue to be resected and willdue to insufficient liver remnant. In a nonhuman primate
model, Dagher et al. (11) demonstrated that definite perform the procedure in the safest and easiest way.
Hepatectomy prior to hepatocyte transplantation hasocclusion of the left and right anterior portal branches
(corresponding to 50% of the liver after left lateral already been done in a series of patients transplanted
for familial hypercholesterolemia in 1992–1994. Theseresection) significantly improved engraftment of hepato-
cytes after autologous cell transplantation and resulted patients underwent left lateral segment sectionectomy to
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